PMID- 34780022
OWN - NLM
STAT- MEDLINE
DCOM- 20211130
LR  - 20220531
IS  - 1179-1918 (Electronic)
IS  - 1173-2563 (Print)
IS  - 1173-2563 (Linking)
VI  - 41
IP  - 12
DP  - 2021 Dec
TI  - Egyptian Atherosclerosis and Vascular Biology Association Consensus on the Use of 
      Sodium Glucose Cotransporter-2 Inhibitors in Heart Failure with Reduced Ejection 
      Fraction.
PG  - 1027-1036
LID - 10.1007/s40261-021-01095-6 [doi]
AB  - Heart failure (HF) is a common cause of cardiovascular mortality and morbidity. 
      Despite advances in treatment, the prognosis remains poor. Sodium-glucose 
      co-transporter 2 (SGLT-2) inhibitors decrease HF events by 27-39% in high-risk 
      patients with type 2 diabetes mellitus (T2DM). Moreover, the DAPA-HF and 
      EMPEROR-Reduced studies randomized patients with HF with reduced ejection 
      fraction (HFrEF) with or without diabetes mellitus to receive guideline-directed 
      medical therapy versus guideline-directed medical therapy plus an SGLT-2 
      inhibitor. Both studies showed the benefits of SGLT-2 inhibitors. In addition, 
      SGLT-2 inhibitors have shown improvement according to the EMPEROR-Preserved study 
      of HF with preserved ejection fraction (HFpEF). Therefore, a panel of cardiology 
      experts from the Egyptian Atherosclerosis and Vascular Biology Association (EAVA) 
      revised the literature for SGLT-2 inhibitors in HF, along with the recommended 
      indications and contraindications, and this article presents their consensus on 
      the topic. The panel concluded that SGLT-2 inhibitors have significantly 
      benefited patients with chronic HFrEF, as indicated through the DAPA-HF and 
      EMPEROR-Reduced trials. The panel recommended early use of dapagliflozin 10 mg or 
      empagliflozin 10 mg in patients with symptomatic chronic HFrEF, whether diabetic 
      or non-diabetic, to ameliorate HF hospitalization rate, mortality, symptoms, and 
      decline in renal function.
CI  - (c) 2021. The Author(s).
FAU - Elserafy, Ahmed S
AU  - Elserafy AS
AD  - Department of Cardiology, Ain Shams University, Cairo, Egypt.
FAU - Reda, Ashraf
AU  - Reda A
AD  - Department of Cardiology, Menufiya University, Menufiya, Egypt.
FAU - Farag, Elsayed
AU  - Farag E
AD  - Department of Cardiology, Zagazig University, Zagazig, Egypt.
FAU - Mostafa, Tamer
AU  - Mostafa T
AD  - Department of Cardiology, Zagazig University, Zagazig, Egypt.
FAU - Farag, Nabil
AU  - Farag N
AD  - Department of Cardiology, Menufiya University, Menufiya, Egypt.
FAU - Elbahry, Atef
AU  - Elbahry A
AD  - Cardiology Unit, Port Foad Centre, Port Foad, Egypt.
FAU - Sanad, Osama
AU  - Sanad O
AD  - Department of Cardiology, Benha University, Behna, Egypt.
FAU - Bendary, Ahmed
AU  - Bendary A
AD  - Department of Cardiology, Benha University, Behna, Egypt.
FAU - Elkersh, Ahmed
AU  - Elkersh A
AD  - Department of Cardiology, Menufiya University, Menufiya, Egypt.
FAU - Attia, Ihab
AU  - Attia I
AD  - Department of Cardiology, Ain Shams University, Cairo, Egypt.
FAU - Selim, Mohammed
AU  - Selim M
AD  - Department of Cardiology, National Heart Institute, Cairo, Egypt.
FAU - Khamis, Hazem
AU  - Khamis H
AD  - Department of Cardiology, October University, 6th of October, Egypt.
FAU - Issak, Emad R
AU  - Issak ER
AUID- ORCID: 0000-0003-4150-649X
AD  - Department of Internal Medicine, Faculty of Medicine, Ain Shams University, 4/45 
      Sector 8, Zahraa Al-Maadi, Cairo, 11442, Egypt. dr.emad.r.h.issak@gmail.com.
LA  - eng
PT  - Consensus Development Conference
PT  - Journal Article
DEP - 20211115
PL  - New Zealand
TA  - Clin Drug Investig
JT  - Clinical drug investigation
JID - 9504817
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
SB  - IM
MH  - *Atherosclerosis/drug therapy
MH  - Biology
MH  - *Diabetes Mellitus, Type 2/diagnosis/drug therapy
MH  - Egypt
MH  - *Heart Failure/diagnosis/drug therapy
MH  - Humans
MH  - *Sodium-Glucose Transporter 2 Inhibitors/therapeutic use
MH  - Stroke Volume
PMC - PMC8626381
COIS- Emad R. Issak has no conflicts of interest to declare. Ahmed S. Elserafy, Ashraf 
      Reda, Elsayed Farag, Tamer Mostafa, Nabil Farag, Atef Elbahary, Osama Sanad, 
      Ahmed Bendary, Ahmed Elkersh, Ihab Attiam, Mohammed Selim and Hazem Khamis have 
      conducted scientific sessions and received honoraria from AstraZeneca, Boehringer 
      Ingelheim, and Sanofi.
EDAT- 2021/11/16 06:00
MHDA- 2021/12/01 06:00
PMCR- 2021/11/15
CRDT- 2021/11/15 12:31
PHST- 2021/10/17 00:00 [accepted]
PHST- 2021/11/16 06:00 [pubmed]
PHST- 2021/12/01 06:00 [medline]
PHST- 2021/11/15 12:31 [entrez]
PHST- 2021/11/15 00:00 [pmc-release]
AID - 10.1007/s40261-021-01095-6 [pii]
AID - 1095 [pii]
AID - 10.1007/s40261-021-01095-6 [doi]
PST - ppublish
SO  - Clin Drug Investig. 2021 Dec;41(12):1027-1036. doi: 10.1007/s40261-021-01095-6. 
      Epub 2021 Nov 15.